Mersana Therapeutics, Inc. (MRSN) Analysts See $-0.50 EPS

January 13, 2018 - By Ellis Scott

 Mersana Therapeutics, Inc. (MRSN) Analysts See $ 0.50 EPS

Analysts expect Mersana Therapeutics, Inc. (NASDAQ:MRSN) to report $-0.50 EPS on February, 8.After having $-0.35 EPS previously, Mersana Therapeutics, Inc.’s analysts see 42.86 % EPS growth. The stock decreased 2.89% or $0.46 during the last trading session, reaching $15.44. About 40,813 shares traded. Mersana Therapeutics, Inc. (NASDAQ:MRSN) has 0.00% since January 13, 2017 and is . It has underperformed by 16.70% the S&P500.

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Ratings Coverage

Among 3 analysts covering Mersana Therapeutics Inc (NASDAQ:MRSN), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Mersana Therapeutics Inc has $2300 highest and $2300 lowest target. $23’s average target is 48.96% above currents $15.44 stock price. Mersana Therapeutics Inc had 3 analyst reports since July 24, 2017 according to SRatingsIntel. Cowen & Co initiated the stock with “Buy” rating in Monday, July 24 report. The stock of Mersana Therapeutics, Inc. (NASDAQ:MRSN) has “Buy” rating given on Monday, July 24 by J.P. Morgan. The firm has “Buy” rating by Leerink Swann given on Monday, July 24.

Mersana Therapeutics, Inc. is a biotechnology firm that discovers, engineers, and develops antibody drug conjugates to cure various cancers. The company has market cap of $351.31 million. The firm develops immune conjugate therapies to create drugs that enhance patients?? lives. It currently has negative earnings. It offers XMT-1522, a drug therapy for tumor models that express relatively low amounts of the HER2 protein; and human anti-HER2 antibody used in XMT-1522.

More notable recent Mersana Therapeutics, Inc. (NASDAQ:MRSN) news were published by: Streetinsider.com which released: “Mersana Therapeutics (MRSN) Reports First Patient Dosed with XMT-1536 in Phase …” on December 12, 2017, also Globenewswire.com with their article: “Mersana Therapeutics Outlines 2017 Milestones and 2018 Goals” published on January 08, 2018, Marketwatch.com published: “Mersana Therapeutics Inc.” on June 05, 2017. More interesting news about Mersana Therapeutics, Inc. (NASDAQ:MRSN) were released by: Seekingalpha.com and their article: “Mersana Therapeutics Kicks Off A Major IPO Week” published on June 26, 2017 as well as Nasdaq.com‘s news article titled: “Cancer biotech Mersana Therapeutics sets terms for $75 million IPO” with publication date: June 16, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: